A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening

Area of Science:

• Virology
• Drug Discovery
• Computational Biology

Background:

• The COVID-19 pandemic necessitates the development of effective therapeutics beyond prophylactic measures.
• Targeting multiple points in the viral life cycle is crucial for combating current and future coronavirus threats.
• Existing treatments are insufficient, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To identify potential therapeutic inhibitors for SARS-CoV-2 using a large-scale virtual screening platform.
• To explore targeting multiple viral and host factors, including active sites and protein-protein interactions.
• To develop a cost-effective and efficient method for discovering novel antiviral agents.

Main Methods:

• Utilized the VirtualFlow platform for ultra-large-scale in silico screening.
• Screened approximately 1 billion molecules against 40 distinct target sites.
• Focused on 17 different viral and host targets, including enzyme active sites and protein-protein interaction interfaces.

Main Results:

• Successfully screened a vast chemical library against multiple SARS-CoV-2 targets.
• Identified potential inhibitor candidates by targeting both enzymatic active sites and critical auxiliary sites.
• Demonstrated the capability of the VirtualFlow platform in large-scale structure-based virtual screening.

Conclusions:

• The study highlights the potential of large-scale virtual screening for discovering SARS-CoV-2 therapeutics.
• Targeting diverse sites, including protein-protein interactions, offers a promising strategy for broad-spectrum coronavirus inhibition.
• The VirtualFlow platform provides a valuable tool for accelerating the development of effective antiviral drugs.